ArticleJournal of translational medicine2025
HLA-A drives diabetic retinopathy pathogenesis: multi-omics integration reveals resveratrol's therapeutic potential via immunomodulation.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundDiabetic retinopathy (DR) remains a leading cause of vision impairment worldwide, with limited therapeutic options and early detection methods. This study aims to identify novel biomarkers for DR to address the critical need for therapeutic targets.
methodsWe employed a multi-omics strategy combining scRNA-seq analysis of DR-related immune cell populations with bidirectional MR integrating quantitative trait loci (eQTL)/protein quantitative trait loci (pQTL) data to establish HLA-A's causal role in DR. Clinical validation utilized Chinese cohort peripheral blood samples (n = 81), complemented by molecular docking and cellular experiments testing resveratrol's modulation of HLA-A under metabolic stress conditions.
resultsBidirectional Mendelian randomization identified HLA-A as a causal risk factor for DR, with consistent evidence from both expression quantitative trait loci (eqtl: OR = 1.121, 95% CI [1.057, 1.19], p = 1.584 × 10
conclusionThis multi-omics study establishes HLA-A as a novel causal factor in DR pathogenesis and reveals resveratrol's potential therapeutic value through HLA-A modulation, providing new insights for targeted intervention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.